Contact
searchSearch
HMP Global
Login

Videos

Ovarian cancer, Rosella trial
Videos
Advancing Treatment in Platinum-Resistant Ovarian Cancer: Clinical Impact of the ROSELLA Trial
03/03/2026
Robert L. Colemen, MD, FACOG, FACS
Robert Coleman, MD, discusses how the phase 3 ROSELLA trial showed that relacorilant plus nab-paclitaxel significantly improved overall survival in patients with platinum-resistant ovarian cancer.
Robert Coleman, MD, discusses how the phase 3 ROSELLA trial showed that relacorilant plus nab-paclitaxel significantly improved overall survival in patients with platinum-resistant ovarian cancer.
Robert Coleman, MD, discusses...
03/03/2026
Journal of Clinical Pathways
Non-small cell lung cancer, NSCLC
Videos
Examining Equity Gaps in Immune Checkpoint Inhibitor Trials for NSCLC
02/25/2026
Adam Barsouk, MD
Adam A. Barsouk, MD, discusses how underrepresentation in NSCLC immunotherapy trials continues to influence survival outcomes and what must change to achieve more equitable care.
Adam A. Barsouk, MD, discusses how underrepresentation in NSCLC immunotherapy trials continues to influence survival outcomes and what must change to achieve more equitable care.
Adam A. Barsouk, MD, discusses...
02/25/2026
Journal of Clinical Pathways
Houda Hachad, PharmD
Videos
Clinical Implications of the FDA’s Capecitabine Boxed Warning: Integrating DPYD Testing into Oncology Practice: Part 2
12/04/2025
Houda Hachad, PharmD
Houda Hachad, PharmD, discusses how emerging US Food and Drug Administration (FDA) actions and expanding pharmacogenomic insights may soon transform fluoropyrimidine safety and reshape precision oncology from diagnosis through survivorship.
Houda Hachad, PharmD, discusses how emerging US Food and Drug Administration (FDA) actions and expanding pharmacogenomic insights may soon transform fluoropyrimidine safety and reshape precision oncology from diagnosis through survivorship.
Houda Hachad, PharmD, discusses...
12/04/2025
Journal of Clinical Pathways
Houda Hachad, PharmD
Videos
Clinical Implications of the FDA’s Capecitabine Boxed Warning: Integrating DPYD Testing into Oncology Practice
12/04/2025
Houda Hachad, PharmD
Learn why mandatory DPYD testing may be just the beginning of a broader shift toward pharmacogenomics-driven safety in cancer treatment.
Learn why mandatory DPYD testing may be just the beginning of a broader shift toward pharmacogenomics-driven safety in cancer treatment.
Learn why mandatory DPYD testing...
12/04/2025
Journal of Clinical Pathways
BDHC thumbnail
Videos
Breaking Down Cancer Prevention: What Really Works?
11/26/2025
John Hennessy, MBA; Michael Kolodziej, MD
In this episode of Breaking Down Health Care, John Hennessy and Dr. Michael Kolodziej explore the crucial difference between cancer screening and true cancer prevention, highlighting how lifestyle changes, vaccines, and emerging therapies...
In this episode of Breaking Down Health Care, John Hennessy and Dr. Michael Kolodziej explore the crucial difference between cancer screening and true cancer prevention, highlighting how lifestyle changes, vaccines, and emerging therapies...
In this episode of Breaking Down...
11/26/2025
Cancer Care Business Exchange
Koulopoulos
Videos
Gigatrends Reshaping Global Health Care: Insights for CPC+CBEx 2025
10/31/2025
Thomas Koulopoulos
Futurist Thomas Koulopoulos explores how “gigatrends”—seismic global shifts like changing demographics and AI—are redefining health care, urging a balance between innovation and trust as the industry evolves toward more human-centered,...
Futurist Thomas Koulopoulos explores how “gigatrends”—seismic global shifts like changing demographics and AI—are redefining health care, urging a balance between innovation and trust as the industry evolves toward more human-centered,...
Futurist Thomas Koulopoulos...
10/31/2025
Journal of Clinical Pathways
CONFERENCE COVERAGE
CAR T-Cell Therapy and Bispecifics in the Community: Opportunities and Obstacles
10/22/2025
Lavi Kwiatkowsky
At CPC+CBEx 2025, Lavi Kwiatkowsky discussed how payer frameworks, accreditation requirements, and operational challenges are shaping access to CAR T-cell and bispecific therapies in community oncology—and how technology could bridge the gap...
At CPC+CBEx 2025, Lavi Kwiatkowsky discussed how payer frameworks, accreditation requirements, and operational challenges are shaping access to CAR T-cell and bispecific therapies in community oncology—and how technology could bridge the gap...
At CPC+CBEx 2025, Lavi...
10/22/2025
Journal of Clinical Pathways
BDHC thumbnail
Videos
Cancer Screening in Transition: From Imaging to Innovation
10/15/2025
John Hennessy, MBA; Michael Kolodziej, MD
In this episode of Breaking Down Health Care, John Hennessy and Dr Michael Kolodziej explore the evolving landscape of cancer screening—from the advances in imaging and artificial intelligence to the promise and pitfalls of new DNA- and...
In this episode of Breaking Down Health Care, John Hennessy and Dr Michael Kolodziej explore the evolving landscape of cancer screening—from the advances in imaging and artificial intelligence to the promise and pitfalls of new DNA- and...
In this episode of Breaking Down...
10/15/2025
Cancer Care Business Exchange
Kuntz
Conference Coverage
Defining the Future of Predictable Cost of Care: Insights from Phase 2
10/10/2025
Gordon Kuntz
The Predictable Cost of Care (PCC) Working Group is expanding its economic models to include patient-centric metrics by developing a parallel track that measures patient time, healthcare interactions, and variability in coverage, aiming to...
The Predictable Cost of Care (PCC) Working Group is expanding its economic models to include patient-centric metrics by developing a parallel track that measures patient time, healthcare interactions, and variability in coverage, aiming to...
The Predictable Cost of Care...
10/10/2025
Journal of Clinical Pathways
Tremonti Headshot
Videos
Evolving Pathways: How Stakeholder Collaboration is Shaping the PCC Model
10/08/2025
Carole Tremonti, RN, MBA
From expanding stakeholder collaboration to tackling data transparency and real-world model testing, the Predictable Cost of Care initiative is transforming how clinical pathways are developed and decisions are driven by data.
From expanding stakeholder collaboration to tackling data transparency and real-world model testing, the Predictable Cost of Care initiative is transforming how clinical pathways are developed and decisions are driven by data.
From expanding stakeholder...
10/08/2025
Journal of Clinical Pathways

Special Reports

Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use